How the FDA black box warning shaped HRT fears

On November 10, 2025, the FDA approved labeling changes for six menopausal hormone therapy products and removed risk statements from boxed warnings related to cardiovascular disease, breast cancer, and probable dementia. The black box warning, tied to early Women’s Health Initiative findings, turned HRT into a shorthand for danger for more than two decades. Many women in perimenopause still hear the older message louder than the newer guidance.

How a warning became a belief

The original FDA action began in 2003, when the agency approved class-wide labeling changes for estrogen and estrogen-progestogen products. Those labels eventually carried a boxed warning that pointed to cardiovascular events, invasive breast cancer, and probable dementia. For patients, that was rarely read as a narrow regulatory caution. It landed as a simple verdict: hormone therapy was risky, full stop.

That message was amplified by the scale and authority of the Women’s Health Initiative, the NIH-supported hormone trial, the largest women’s health study in the United States. The WHI hormone program included two studies, one for estrogen-plus-progestin in women with a uterus and one for estrogen-alone in women without a uterus. The estrogen-plus-progestin arm enrolled 16,608 postmenopausal women aged 50 to 79 with an intact uterus, recruited by 40 U.S. clinical centers from 1993 to 1998.

What got lost in the public memory is that the WHI was designed around disease prevention, not around treating the day-to-day symptoms that drive women to ask about HRT in the first place. A study built to measure long-term health outcomes can produce headlines that feel absolute, even when they do not answer the more immediate question facing a person in the exam room: will this help my hot flashes, sleep loss, mood swings, or other quality-of-life symptoms?

Why the old message stuck

Perimenopause is often discussed in abstractions, but the lived symptoms are concrete. Women come in with sleep disruption, hot flashes, and changes in mood, and they are trying to decide whether relief is worth the tradeoff. The black box warning made that decision feel like a gamble, even for women who might otherwise have been reasonable candidates for treatment.

The broader confusion persisted because the warning was never just about menopause symptom control. It bundled together the WHI findings, broader fears about cardiovascular disease, breast cancer, stroke, and later probable dementia, then sat on product labels long enough to shape culture as much as prescribing. By the time clinicians were talking more openly about formulation, dose, age, and timing, many patients had already absorbed a simpler lesson: avoid hormones unless you have no other choice.

What the FDA changed in 2025

The agency revisited the issue directly on July 17, 2025, when it convened an expert panel on menopause and hormone replacement therapy for women. The November 10 labeling changes were meant to clarify benefit-risk considerations, not to imply that hormone therapy is risk-free, the FDA and HHS said.

The agency did not declare that HRT has no risks. It said the labels should better reflect the balance of benefits and harms rather than preserve a warning structure that many clinicians felt had become too blunt for modern menopause care.

For women who started hearing the word “hormones” as a warning in the early 2000s, the label itself became part of the memory. Removing broad boxed-warning language does not erase two decades of cautionary messaging overnight, especially when many patients still remember HRT as something their mothers were advised against.

Who may benefit, and where caution still matters

Current menopause guidance has moved toward a more individualized view. The North American Menopause Society updated its hormone therapy position statement in 2022, and ACOG recognizes hormone therapy as a treatment for symptoms of menopause and perimenopause. Treatment decisions should be based on symptom burden, age, time since menopause, and the person’s overall risk profile.

A widely used rule of thumb is the timing hypothesis: many clinicians expect benefits to outweigh risks for healthy women younger than 60 or within 10 years of menopause onset. It is a framework for why the same medication can look different on the risk-benefit scale depending on when it is started.

This is also where the WHI’s legacy remains useful, if it is read carefully. The trial helped identify real harms in some settings, but it also became the basis for a public fear that was broader than the evidence supported. Modern prescribing is more specific than that old debate: it asks who is being treated, which formulation is being used, and what symptom pattern is in front of the clinician.

Why low-dose vaginal estrogen is treated differently

Not all estrogen therapy belongs in the same conversation. Low-dose vaginal estrogen is usually discussed separately because it is used for local genitourinary symptoms and has minimal systemic absorption. That makes it unlike whole-body hormone replacement, and it is one reason clinicians and advocacy groups have pushed for more precise language around menopause treatment.

Some forms are targeted, low-dose, and designed for specific symptoms. The old black box language blurred those lines.

What to bring to a GP visit

If perimenopause is disrupting sleep, mood, or daily function, that is the point to raise HRT with a GP rather than wait for symptoms to get worse. The most useful discussion is a specific one: what symptoms are you treating, how far you are from menopause onset, and whether you are being offered systemic therapy or low-dose vaginal estrogen. Those details matter because the risk conversation changes with the formulation, the timing, and the goal.